Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Neben

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agentsM Merz, K Neben, M S Raab, et al.
Leukemia|August 21, 2013
Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significanceJ Hillengass, M-A Weber, K Kilk, et al.
Oncogene|February 22, 2007
Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19qB Tews, P Roerig, C Hartmann, et al.
Leukemia|February 19, 2014
Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myelomaM Merz, T Hielscher, B Wagner, et al.
American Journal of Hematology|August 1, 2012
Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphomaF McClanahan, T Hielscher, M Rieger, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Leukemia|February 10, 2016
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IVM B Miranda, M Lauseker, M-P Kraus, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agentsM Merz, K Neben, M S Raab, et al.
Leukemia|August 21, 2013
Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significanceJ Hillengass, M-A Weber, K Kilk, et al.
Oncogene|February 22, 2007
Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19qB Tews, P Roerig, C Hartmann, et al.
Leukemia|February 19, 2014
Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myelomaM Merz, T Hielscher, B Wagner, et al.
American Journal of Hematology|August 1, 2012
Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphomaF McClanahan, T Hielscher, M Rieger, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Leukemia|February 10, 2016
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IVM B Miranda, M Lauseker, M-P Kraus, et al.
Pageof 3